Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Yahoo Finance • 3 days ago

3 Biotech Stocks To Watch In October 2026

Rising U.S. interest rate expectations, highlighted by the St. Louis Fed hinting at possible hikes over the next 6 to 9 months, keep pressure on expensive, story driven assets. That focus on higher borrowing costs puts a premium on medical... Full story

Yahoo Finance • 3 days ago

Catalyst watch: Big bank earnings, CPI, and the Paris Auto Show

[Finance background] honglouwawa Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - OCTOBER 12 *... Full story

Yahoo Finance • 30 days ago

Goldman rebalances its long duration stock basket

[Interest rate percentage sign symbol finance investment graph chart] alexsl The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates. Equities usually struggle to digest sharp increases in interes... Full story

Yahoo Finance • 30 days ago

Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets. On Friday, the Dow Jones Industria... Full story

Yahoo Finance • last month

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Making its debut on 03/01/2006, smart beta exchange traded fund Invesco S&P MidCap 400 Pure Growth ETF (RFG) provides investors broad exposure to the Style Box - Mid Cap Growth category of the market. What Are Smart Beta ETFs? Products t... Full story

Yahoo Finance • last month

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

Michael S. Perry, a Director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value $1 million Shares sold 11... Full story

Yahoo Finance • last month

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/d... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - - Arrowhead will host a webcas... Full story

Yahoo Finance • 2 months ago

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

This article first appeared on GuruFocus. Net Loss: $194.3 million, or a loss of $1.36 per share, for the fiscal 2026 third quarter ended June 30, 2026. Revenue: Approximately $75 million for the quarter, up from $28 million in the prior... Full story

Yahoo Finance • 3 months ago

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket. Continue Reading... Full story

Yahoo Finance • 3 months ago

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

[Up Down Arrows. Green And Red Color] Arrowhead Pharmaceuticals (ARWR [https://seekingalpha.com/symbol/ARWR]) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in patients with severe hypertriglyceridem... Full story

Yahoo Finance • 3 months ago

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London. Continue Reading... Full story

Yahoo Finance • 4 months ago

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Quick Read Crinetics Pharmaceuticals leads as the cleanest buyout candidate at $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb or Novartis but costs $10.86 billion. ARWR's ARO-INHBE nearly doubled tirzepati... Full story

Yahoo Finance • 5 months ago

Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its... Full story

Yahoo Finance • 5 months ago

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

DelveInsight Business Research LLP The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel therapeut... Full story

Yahoo Finance • 6 months ago

Stocks Erase Early Gains as Crude Prices Jump on Iran Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.02%.  June E-mini S&P futures (ESM26) are down -0.13%, and June E-mini Nasd... Full story

Yahoo Finance • 7 months ago

Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commer... Full story

Yahoo Finance • 8 months ago

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts expected later this year, including key Phase 3 SH... Full story

Yahoo Finance • 8 months ago

Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline

Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q1 2026 MANAGEMENT VIEW * Dr. Christopher Anzalone, Chairman, CEO & President, stated, "We had another quarter of strong execution across all areas of our business, and we are we... Full story

Yahoo Finance • 8 months ago

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ...

This article first appeared on GuruFocus. Net Income: $30.8 million for the quarter ended December 31, 2025. Earnings Per Share (EPS): $0.22 per share based on 140.7 million fully diluted weighted average shares outstanding. Revenue: $264... Full story